New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
19:53 EDTCVR, VMI, BMY, TISI, IMSOn The Fly: After Hours Movers
HIGHER: IMS Health Holdings (IMS), up 5.13% after acquiring certain Cegedim businesses for $520M... Bristol-Myers Squibb (BMY), up 1.97% after a Phase 3 study of nivolumab was halted early due to superior data. LOWER: CVR Refining (CVR), down 4.05% after filing a secondary offering. DOWN AFTER EARNINGS: Team (TISI), down 7.27%... Valmont Industries (VMI), down 5.71% after lowering its FY14 EPS view.
News For IMS;BMY;CVR;TISI;VMI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
13:55 EDTBMYRBC thinks Intercept values itself more than any bidder can pay
RBC Capital analyst Michael Yee believes Intercept Pharmaceuticals (ICPT) thinks it is worth more than a bidder would be willing to pay at this time. Suitor interest is not surprising given Intercept's pending approval in the summer, but a near-term takeover is unlikely since the FDA hasn't even held a panel meeting for the company's lead drug OCA, Yee tell investors in a research note after Reuters reported that the company received interest and is exploring a possible sale. The analyst thinks Intercept could be synergistic for companies like Gilead (GILD), Merck (MRK), Bristol-Myers (BMY), Sanofi (SNY) and AstraZeneca (AZN). Yee has an Outperform rating on stock with a $300 price target. Intercept is rallying 25%, or $24.07, to $118.36 in afternoon trading.
12:51 EDTBMYIntercept said to explore sale after suitors reportedly come calling
Shares of Intercept Pharmaceuticals (ICPT), which has often been rumored in the past to be a potential takeover target, are surging in afternoon trading after Reuters reported that the company is exploring a potential sale. WHAT'S NEW: Reuters, citing people familiar with the matter, said the company, which focuses on treatments for liver disease, has been working with investment banker advisors to explore a sale after receiving interest from other companies. PRIOR CHATTER: Earlier this week, United Kingdom blog Proactive Investors discussed "reheated rumors" of a takeover of Intercept, which claimed the company was teaming up with CenterView Partners to advise on a sale. It mentioned AstraZeneca (AZN) as a possible suitor now that Shire (SHPG) has reached an agreement to acquire Baxalta (BXLT). On February 2, the U.K.'s Daily Mail said rumors that several big-name pharmaceutical companies were interested in Intercept had been "doing the rounds again," noting that trader chatter pointed to purported interest from Shire, Gilead (GILD), Bristol-Myers (BMY) and Pfizer (PFE). WHAT'S NOTABLE: Yesterday, the FDA issued a notice to announce a forthcoming meeting of the Gastrointestinal Drugs Advisory Committee to discuss the new drug application for obeticholic acid oral tablets submitted by Intercept Pharmaceuticals, proposed for the treatment of primary biliary cirrhosis in combination with ursodeoxycholic acid in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. PRICE ACTION: In afternoon trading, Intercept jumped 35% to $127.85 per share. Reference Link
February 11, 2016
10:01 EDTTISIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Artisan Partners (APAM) upgraded to Neutral from Sell at Citi... Ascena Retail (ASNA) upgraded to Neutral from Sell at Goldman... Becton Dickinson (BDX) upgraded to Buy from Hold at Deutsche BankvCisco (CSCO) upgraded to Buy from Hold at Jefferies... C.H. Robinson (CHRW) upgraded at Buckingham... Crown Castle (CCI) upgraded to Conviction Buy from Buy at Goldman... Euronet (EEFT) upgraded to Outperform from Market Perform at Avondale... FibroGen (FGEN) upgraded to Outperform from Neutral at Credit Suisse... First Data (FDC) has hit 'rock bottom,' shares upgraded to Outperform at Credit Suisse... Horace Mann (HMN) upgraded to Buy from Neutral at Janney Capital... Hortonworks (HDP) upgraded to Neutral at Susquehanna... Level 3 (LVLT) upgraded to Overweight on valuation at Morgan Stanley... NCI, Inc. (NCIT) upgraded to Buy from Neutral at SunTrust... Omega Healthcare (OHI) upgraded on results, valuation at JMP Securities... Sun Life Financial (SLF) upgraded to Outperformer from Sector Performer at CIBC... Tanger Factory (SKT) upgraded to Buy from Neutral at Hilliard Lyons... Team (TISI) upgraded to Overweight from Sector Weight at KeyBanc... Tenneco (TEN) upgraded to Overweight from Equal Weight at Barclays... Time Warner (TWX) upgraded to Conviction Buy at Goldman... Ulta Beauty (ULTA) upgraded to Strong Buy from Outperform at Raymond James... Voya Financial (VOYA) upgraded to Neutral from Underweight at JPMorgan... Western Alliance (WAL) upgraded to Buy from Neutral at DA Davidson.
February 10, 2016
16:22 EDTTISITeam upgraded to Overweight from Sector Weight at KeyBanc
February 8, 2016
07:25 EDTBMYBiotech Industry Organization to hold a conference
Subscribe for More Information
06:28 EDTBMYPharma trade group rolls out ad campaign aimed at lawmakers, WSJ says
The pharmaceutical industry is launching a new ad campaign with the intention of improving its reputation with lawmakers in an effort to lobby against drug price restrictions, the Wall Street Journal reports. The industry's biggest trade group the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it plans to spend several million dollars this year, and 10% more than it spent last year, on digital, radio, and print advertisements that highlight the sector's role in developing new drugs and advancing medical science, the report says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
February 5, 2016
12:48 EDTBMYBristol-Myers announces expanded use of Daklinza approved by FDA
Bristol-Myers Squibb announced today that Daklinza, an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration in combination with sofosbuvir (with or without ribavirin) in genotypes 1 and 3. The expanded label includes data in three additional challenging-to-treat patient populations: chronic hepatitis C virus patients with HIV-1 coinfection, advanced cirrhosis, or post-liver transplant recurrence of HCV. The Daklinza plus sofosbuvir regimen is already available for the treatment of chronic HCV genotype 3, and is currently the only 12-week, once-daily all-oral treatment option for these patients. Sustained virologic response rates are reduced in genotype 3 patients with cirrhosis receiving Daklinza and sofosbuvir for 12 weeks without ribavirin. The recommended dosage of Daklinza is 60 mg in combination with sofosbuvir with or without ribavirin for 12 weeks.
07:37 EDTBMYBristol-Myers pullback brings buying opportunity, says JPMorgan
JPMorgan analyst Chris Schott sees an attractive opportunity for shares of Bristol-Myers following the recent pullback. He reiterates an Overweight rating on the name with an $80 price target. The analyst sees a number of Immuno-Oncology catalysts for shares of Bristol over the next 12-18 months.
February 3, 2016
07:14 EDTIMSIMS Health sees cash tax rate to remain in high teens through mid-2023
Subscribe for More Information
07:13 EDTIMSIMS Health sees FY16 constant currency adjusted EPS growth 8.5%-10.5%
Subscribe for More Information
07:11 EDTIMSIMS Health reports Q4 adjusted EPS 37c, consensus 32c
Subscribe for More Information
February 2, 2016
13:35 EDTBMYEarnings Watch: Merck down over 5% since last earnings report
Subscribe for More Information
09:46 EDTBMYIntercept rumored to draw interest from many suitors, Daily Mail says
Subscribe for More Information
08:53 EDTBMYPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
February 1, 2016
06:58 EDTBMYPortola Pharma licensed right to andexanet alfa to Bristol-Myers and Pfizer
Subscribe for More Information
06:57 EDTBMYBristol-Myers and Pfizer sign collaboration with Portola Pharmaceuticals
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use